Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.

MLA

Sundy JS, et al. “Reduction of Plasma Urate Levels Following Treatment with Multiple Doses of Pegloticase (Polyethylene Glycol-Conjugated Uricase) in Patients with Treatment-Failure Gout: Results of a Phase II Randomized Study.” Arthritis & Rheumatism, vol. 58, no. 9, Sept. 2008, pp. 2882–91. EBSCOhost, https://doi.org/10.1002/art.23810.

APA

Sundy JS, Becker MA, Baraf HSB, Barkhuizen A, Moreland LW, Huang W, Waltrip RW II, Maroli AN, Horowitz Z, & Pegloticase Phase 2 Study Investigators. (2008). Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis & Rheumatism, 58(9), 2882–2891. https://doi.org/10.1002/art.23810

Chicago

Sundy JS, Becker MA, Baraf HSB, Barkhuizen A, Moreland LW, Huang W, Waltrip RW II, Maroli AN, Horowitz Z, and Pegloticase Phase 2 Study Investigators. 2008. “Reduction of Plasma Urate Levels Following Treatment with Multiple Doses of Pegloticase (Polyethylene Glycol-Conjugated Uricase) in Patients with Treatment-Failure Gout: Results of a Phase II Randomized Study.” Arthritis & Rheumatism 58 (9): 2882–91. doi:10.1002/art.23810.